AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 271 min read$NAUT

Nautilus Biotechnology 3Q 2026: Revenue $234K, Net loss ($15.64M), EPS ($0.12) — 10-Q Summary

Nautilus Biotechnology reported 3Q 2026 revenue of $234K, up from $0 a year earlier, with a net loss of $15.64M and EPS loss of $0.12. Revenue came from research grants and services. The company plans 2027 pre-orders for its Voyager instrument and is adjusting assay development focus.

Original reporting
tradingview.com
Published Oct 27, 2026, 11:41 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 11:45 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Nautilus Biotechnology 3Q 2026: Revenue $234K, Net loss ($15.64M), EPS ($0.12) — 10-Q Summary — source image
Source · tradingview.com
Decision brief

The 30-second read

$NAUTBearishLow
01

Why it matters

The earnings release shows minimal revenue and a widening net loss, which is likely to trigger a sell‑off in a thinly traded stock.

02

Market read

Micro‑cap biotech earnings with a loss; limited broader market effect.

03

What to watch

Upcoming Voyager instrument pre‑orders and potential commercial assay launches could improve future revenue.

Relevance 5/10Novelty 5/10Timing: after-hours release

Background

Nautilus Biotechnology (NASDAQ: NAUT) is a small‑cap company developing proteomics platforms. The 10‑Q covers its third quarter of 2026.

Company-level read

Ticker impact

$NAUTBearishMedium confidence
Context

Q3 2026 10‑Q shows $234K revenue, $15.64M net loss and EPS -$0.12, the first earnings disclosure for Nautilus Biotechnology.

Expected impact

likely downward pressure as investors price in the larger loss and minimal revenue

Evidence & confidence

The company posted a loss that exceeds the prior quarter and revenue remains negligible, suggesting limited near‑term upside.

Market effects

Sector

Highlights continued funding challenges for early‑stage proteomics biotech firms.

Regional

Limited to US micro‑cap biotech segment.

Global

Minimal global impact due to small scale.

Counterpoint

What could challenge this read

If the grant funding signals a pipeline that could scale, the stock may be undervalued despite the loss.

Key entities

  • company
    Nautilus Biotechnology

    US‑listed biotech developing proteomics instruments.

Read at source← All news

Related articles

OCT 26
$NAUTLow

Nautilus Biotechnology Reports Third Quarter 2026 Financial Results

Nautilus Biotechnology, Inc. (NAUT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Nautilus Biotechnology Reports Third Quarter 2026 Financial Results SEATTLE, WA, October 27, 2026 – Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the third quarter

SEC EDGAR 8-K2 min
JUL 27
$NAUTMed

Nautilus Biotechnology Reports Second Quarter 2026 Financial Results

Nautilus Biotechnology, Inc. (NAUT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991-q2268xkearnings.htm EX-99.1 Document Exhibit 99.1 Nautilus Biotechnology Reports Second Quarter 2026 Financial Results SEATTLE, WA, July 28, 2026 – Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform,

SEC EDGAR 8-K6 min
OCT 27
$VFCHigh

VF Corporation faces earnings test as Vans turnaround hangs in balance

VF Corporation (VFC) reports Q2 2027 earnings on Wednesday, with investors focused on the Vans brand's recovery. The company expects $0.53 EPS on $2.66B revenue, a turnaround from last quarter's loss. Analysts expect a 5% revenue decline but watch for signs of sequential improvement and guidance updates. VFC's stock has risen 30% from September lows, with a consensus price target of $18.96.

investing.com2 min
OCT 27
$HLTHighAI 8/10

Hilton Worldwide 3Q 2026: Revenue $3.33B, EPS $2.37— 10-Q Summary

Hilton Worldwide reported 3Q 2026 revenue of $3.33B, up 6.6% YoY, and net income of $536M, up 27.6% YoY. EPS was $2.37. The company opened 520 hotels and added 55,500 net rooms in the first nine months. Systemwide RevPAR rose 5.8%, with U.S. RevPAR up 7.0% and Europe up 6.5%. Hilton Honors membership grew 15% YoY to 270 million. The company noted potential delays in hotel openings due to inflation and interest rates.

tradingview.com1 min